Animal models of Alzheimer's disease: experimental cholinergic denervation

Brain Research Reviews

Volumn 13, Issue 2, 1988, Pages 103-118

  Smith, Gwenn ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Alzheimer's disease; Animal model; Cholinergic system; Ethylcholine mustard aziridinium ion (AF64A); Nucleus basalis of Meynert; Scopolamine

Indexed keywords

ARECOLINE; NEUROTOXIN; PHYSOSTIGMINE; PILOCARPINE; SCOPOLAMINE;

ALZHEIMER DISEASE; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN INJURY; CHOLINERGIC SYSTEM; COGNITION; HISTOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MEYNERT BASAL NUCLEUS; NONHUMAN; PSYCHOLOGICAL ASPECT; REVIEW;

EID: 0023929304     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-0173(88)90016-1     Document Type: Review

References (89)

1. Further characterizations of the nature of the behavioral and neurochemical effects of lesions to the nucleus basalis of Meynert in the rat
2. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease
3. Effects of intrahippocampal injections of the cholinergic neurotoxin AF64A on open-field activity and avoidance learning in the rat
4. Pharmacological investigations of neurotransmitter involvement in passive avoidance responding: a review and some new results
5. Scopolamine induces an increase in muscarinic receptor level in rat hippocampus
6. Cortical projections from somatostatin neurons of the basal forebrain in the rat
7. Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methyphenidate with scopolamine
8. Selective memory loss following nucleus basalis lesions: long term behavioral recovery despite persistent cholinergic deficiencies
9. Patterns of memory failure after scopolamine treatment: implications for cholinergic hypothesis of dementia
10. Denervation supersensitivity in the cholinergic septohippocampal pathway: a microiontophoretic study
11. Quinolinic acid neurotoxicity in the nucleus basalis antagonized by kynurenic acid
12. AF64A induced cholinotoxicity: behavioral and biochemical correlates
13. Differential effects of cholinergic blockade on performance of rats in the water tank navigation task and in a radial arm maze
14. Dopamine neurons in pars compacta of the substantia nigra contain acetylcholinesterase: histochemical correlations on the same brain section
15. Effects of ganglioside treatment in rats with a lesion of the cholinergic forebrain nuclei
16. Stability of neuronal number in the human nucleus basalis of Meynert with age
17. Neuron-specific cytotoxins
18. The use of excitatory amino acids as selective neurotoxins
19. Neurotransmitter specific alterations in dementing disorders: insights from animal models
20. Effects of the novel compound aniracetam (R013-5057) upon impaired learning and memory in rodents
21. Reduced somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type
22. Selective loss of central cholinergic neurons in Alzheimer's disease
23. Analysis of muscarinic receptor concentration and sub-types following lesions of the rat substantia innominata
24. Vinpocetine: nootropic effects on scopolamine induced and hypoxia induced retrieval deficits of a step through passive avoidance response in rats
25. Memory and cognitive function in man: does the cholinergic system have a specific role?
26. Human memory and the cholinergic system
27. Profound disturbances of spontaneous and learned behaviors following lesions of the nucleus basalis magnocellularis in the rat
28. Functional and neurochemical cortical cholinergic impairment following neurotoxic lesions of the nucleus basalis magnocellularis in the rat
29. The nucleus basalis of Meynert
30. Transplantation of embryonic ventral forebrain neurons to the neocortex of rats with lesions of the nucleus basalis magnocellularis. I. Biochemical and anatomical observations
31. The AF64A treated rat as an experimental model for Alzheimer's disease: a critical evaluation
32. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex
33. Scopolamine effects on memory retention in mice: a model of dementia?
34. 18F]fluorodeoxyglucose
35. Loss of cholinergic neurons in rat neocortex produces deficits in passive avoidance learning
36. Test profile of cholinergic dysfunction and of Alzheimer-type dementia
37. Scopolamine does not disrupt spatial working memory in rats
38. Pharmacological alleviation of cholinergic lesion induced memory deficits in rats
39. Chronic intraventricular injections of nerve growth factor elevate hippocampal choline acetyltransferase activity in adult rats with partial septo-hippocampal lesions
40. Lesions in nucleus basalis magnocellularis and medial septal area of rats produce qualitatively similar memory impairments
41. Effects of cholinergic and monoaminergic antagonists and tranquilizers upon spatial memory in rats
42. Spontaneous, cholinergic-dependent, behavioral recovery following basal forebrain lesions in rats
43. Behavioral and neurochemical effects of intraventricular administration of AF64A in rats
44. Laminar distribution of cholinergic markers in neocortex: effects of lesions
45. Histochemical and electron microscopic study of the brain of the AF64A treated rat
46. Basal forebrain lesions produce a dissociation of trial-dependent and trial-independent memory performance
47. Specific toxic effects of ethylcholine nitrogen mustard on cholinergic neurons of the nucleus basalis
48. Deoxyglucose uptake and choline acetyltranferase activity in cerebral cortex following lesions of the nucleus basalis magnocellularis
49. A longitudinal examination of the behavioral and biochemical deficits produced by ibotenate lesions of the rat nucleus basalis magnocellularis
50. Cortical cholinergic impairment and behavioral deficits produced by kainic acid lesions of rat magnocellular basal forebrain
51. Lesions of the cholinergic forebrain nuclei: changes in avoidance behavior and scopolamine actions
52. Decreased cortical glucose utilization after ibotenate lesion of the rat ventromedial globus pallidus
53. Chronic administration of cholinergic agents: effects on behavior and calmodulin
54. Possible mechanisms involved in the presynaptic cholinotoxicity due to ethylcholine aziridinium (AF64A) in vivo
55. Selective presynaptic cholinergic neurotoxicity following intrahippocampal AF64A injection in rats
56. Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation
57. Regulation of neocortical muscarinic receptors: effects of drug treatments and lesions
58. Somatostatin is not co-localized in cholinergic neurons innervating the rat cerebral cortex-hippocampal formation
59. The cholinergic enervation of the cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata) and hypothalamus in the rhesus monkey
60. Lesioning of the rat basal forebrain leads to memory impairments in passive and active avoidance tasks
61. Studies on the content synthesis and disposition of quinolinic acid in physiology and pathology
62. Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine
63. Pilocarpine and physostigmine attenuate spatial memory impairments produced by lesions of the nucleus basalis magnocellularis
64. Alzheimer's-like neuropathology in cortex and hippocampus induced by long-term nucleus basalis magnocellularis (NBM) lesioning in the rat
65. Hypertrophy of immunohistochemically identified cholinergic neurons of the basal nucleus of Meynert following ablation of the contralateral cortex in the rat
66. Effects of ibotenic acid lesions of the basal forebrain on serial reversal learning in the marmoset
67. Learning impairments following lesion of the basal nucleus of Meynert: modification by cholinergic drugs
68. Reversal of scopolamine induced amnesia of passive avoidance by pre and post training naloxone
69. Cortical projections arising from the basal forebrain: a study of cholinergic and noncholinergic components employing combined retrograde tracing and immunohistochemical localization of choline acetyltransferase
70. Impairment in t-maze reinforced alternation performance following nucleus basalis magnocellularis lesions in rats
71. Consistent improvement in memory with long-term oral physostigmine therapy in Alzheimer's disease
72. Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer type: possible role in cell loss
73. Excitotoxic models for neurodegenerative disorders
74. Changes in β-adrenergic receptor subtypes in Alzheimer-type dementia
75. Alzheimer's disease: monoamines and spiperone binding reduced in nucleus basalis
76. Novel approaches in the study of acetylcholine function: neuropharmacology, neuroanatomy and behavior
77. Oral tetrahydroaminoacridine in long-term treatment of senile dementia Alzheimer type
78. Pharmacological challenge strategies in Alzheimer's disease: basic and clinical issues
79. Use of the scopolamine treated rat as an animal model for Alzheimer's disease: amnestic effects, reductions in regional brain energy metabolism and reversal by the nootropic agent piracetam
80. AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex and produces long-term passive avoidance and radial-arm maze deficits in the rat
81. Effects of bilateral ibotenate-induced lesions of the nucleus basalis magnocellularis upon selective cholinergic biochemical markers in the rat anterior cerebral cortex
82. The effect of scopolamine on local glucose metabolism in rat brain
83. Nucleus basalis magnocellularis: optimal coordinates for selective reduction of choline acetyltransferase in frontal neocortex by ibotenic acid injection
84. 3H]Ketanserin (serotonin type 2) binding increases in rat cortex following basal forebrain lesion with ibotenic acid
85. Recovery of neocortical choline acetyltransferase activity following ibotenic acid injection into the nucleus basalis of Meynert in rats
86. Disruption of central cholinergic systems in the rat brain by basal forebrain lesions or atropine: effects on feeding, sensorimotor behavior, locomotor activity and spatial navigation
87. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain
88. Differential effects of scopolamine on working and reference memory of rats in the radial maze
89. Studies of cortical glutamate receptors in nucleus basalis lesioned rats